TO THE EDITOR
The recent correspondence by Ayuk et al 1 confirms the potential of donor lymphocyte infusions (DLI) to mediate anti-myeloma activity (graft-versus-myeloma, GvM) following allogeneic haematopoietic stem cell transplantation (HSCT). The response rate of 38% (4/21 complete, 4/21 partial response) in a group of patients who had undergone a reduced-intensity T-cell-depleted transplantation appears similar to that achieved following fullintensity transplantation and subsequent DLI (36-52%). 2, 3 In the largest series to date, the overall response rate was 52% (9/54 complete, 19/54 partial response). 4 We have documented similar response rates to those of Ayuk et al to equivalent doses of DLI following an alternate T-cell-depleted reduced-intensity regimen (fludarabine 150 mg/m 2 , melphalan 140 mg/m 2 , alemtuzumab 100 mg) in patients with myeloma. 5 In our series, DLI was administered for persistent disease from 6 months post-transplantation, or progression/relapse at any time point after transplantation. We used an initial cell dose of 1 Â 10 6 CD3 þ T cells/kg for both unrelated and HLA-identical related DLI. Dose escalation was carried out in a similar way to Ayuk et al if no response or graft-versus-host disease (GvHD) occurred after 3 months. The escalating doses were 3 Â 10 6 , 1Â 10 7 , 3Â 10 7 and 1 Â 10 8 CD3 þ cell/kg. Of 19 patients (12 matched related donor, seven unrelated donor), 10 (53%) had a response (one complete, eight partial, one minimal). As with other investigators, 1, 4 we found that response was significantly associated with the development of GvHD (P ¼ 0.02). 5 To our knowledge, only one group has reported GvM following DLI in a significant number of patients in the absence of GvHD. 6 Whether this related to the use of CD8 þ depleted DLI (the CD4 þ T cells perhaps recruiting CD8 þ T cells already present within the patient) requires further investigation in larger numbers of patients.
Thus, the data from DLI following reduced-intensity transplantation currently suggest that the GvM activity does not differ significantly in terms of response rates to that following fullintensity transplantation. The early series suggested that responses following full-intensity approaches were uncommon with doses of T cells less than 1 Â 10 8 /kg, 2,3 although cell dose has not been confirmed as a major determinant for response in a more recent updated series. Only two of our responding patients received doses of 1 Â 10 8 /kg or greater. These results, combined with those of Ayuk et al, suggest that responses may be achieved with lower cell doses. Both series also demonstrate the potential for enhanced toxicity in the unrelated DLI cohort, even at the lowest DLI dose, and conclude that starting doses of below 1 Â 10 6 CD3 þ cells/kg may be more appropriate for these patients. A major issue that cannot be addressed in the study of Ayuk et al due to relatively short follow-up (median 221 days from DLI) is that of response durability. With a median followup of 636 days from initial DLI (1215 days in the surviving patients), only two of our responding patients have not progressed (Figure 1) , and one of these died at 130 days post DLI secondary to GvHD. Whether this lack of durability of response in the vast majority reflects maximal T-cell dose, initial T-cell dose, low incidence of complete response following DLI (which could itself be related to either of the former) or some feature peculiar to our reduced intensity approach remains unclear. It may equally be that assessment of larger patient numbers would reveal no significant differences compared to the results achieved after full-intensity transplantation. In this respect, the longer-term follow-up of series such as that of Ayuk et al will be important. The more recent follow-up of DLI-responsive patients after full-intensity transplants reveals a similarly poor durability of responses in those patients who achieve only a partial response following DLI, but an apparently superior durability, and perhaps long-term disease-free survival, in the small group achieving a complete response (four of nine remaining in remission at over 5 years following DLI). 4 The incidence of complete responses in larger numbers of patients with myeloma undergoing dose-escalating DLI starting at relatively low doses of DLI, and the durability of responses in these cases may be informative in planning optimal DLI strategies, but resolution of the answers will likely require more widespread collaboration between transplant centres. It would currently appear that patients achieving less than a complete response have a relatively poor outcome. These patients should be candidates for further escalation of DLI if not precluded by GvHD, or alternate experimental interventions. The role of cytoreductive therapy prior to DLI in order to try to enhance the complete response rate remains unclear.
Figure 1
Kaplan-Meier plot of time to treatment failure (progression/relapse) in patients showing an initial response to DLI (n ¼ 10).
The combined experience to date with DLI suggests that only a minority of patients with myeloma (probably less than 15%) will experience long-term benefit from current approaches to its application, and this must be balanced against the morbidity associated with chronic GvHD. However, it does provide optimism for the possibility of the development of more refined, antigen-specific strategies. All of our responding patients had conversion to multilineage full donor chimerism (assessed by means of polymerase chain reaction analysis of informative minisatellite regions (short tandem repeat (STR) loci)), suggesting that allogeneic rather than tumor-specific targets may be important in mediating responses. This suggestion is supported by the crossreactivity of cytotoxic T-cell clones derived following DLI with both normal and malignant host cells, 7 but does not exclude the coincident development of separate populations mediating GvM and GvHD activity. Indeed, other investigators have isolated and characterised apparently tumorspecific CD8 þ T-cell clones in patients with relapsed myeloma responding to DLI. 8 Attempts at donor vaccination against patient idiotype in order to selectively enhance GvM activity have been limited by the generation of mainly CD4 þ T-cell responses, but advances in DNA vaccine generation now allow this issue to be readdressed. Further knowledge of the mechanisms of response both in terms of effectors and their targets, and of the mechanisms of subsequent immune evasion will likely be required to translate initial optimism into therapeutic reality for patients with myeloma. 
